StockWatch
·

DMCC Speciality Chemicals Ltd Q1 FY27 Results

DMCCQ1 FY27 Results
Filing
Result:Good· Market: SurgedBroad basedBase effectRecord quarter
MetricValueQ4 FY26Q1 FY26
Revenue253.01 Cr42.4%99.2%
Total Income253.31 Cr42.5%98.8%
Expenditure226.10 Cr35.4%94.3%
PBT27.21 Cr151.7%146.7%
Net Profit20.40 Cr166.6%163.1%
OPM13.49%3.53pp0.21pp
NPM8.06%3.76pp1.97pp
EPS8.18166.4%163.0%
View full financials

Revenue nearly doubled and adjusted PAT rose 163% YoY with no exceptionals, but EBITDA margin barely moved (13.28%→13.49%) as raw-material costs rose in lockstep, and the scale of growth off a management-flagged weak FY25-26 base points to base-effect-driven volume recovery rather than a top-tier margin-led beat.

Q1 FY-2027 RESULTS · DMCC

DMCC Q1 FY27: consolidated revenue nearly doubles YoY, PAT surges 163% to ₹20.4 Cr

PAT +163.04% YoY · revenue +99.16% · margins expanding

10 Aug 2026 · 3 min read
Revenue

₹253.01 Cr

+99.16% YoY

PAT (consolidated)

₹20.4 Cr

+163.04% YoY

Net margin

8.05%

+2pp YoY

EPS

₹8.18

DMCC Speciality Chemicals reported a strong Q1 FY27 (quarter ended June 30, 2026): consolidated revenue nearly doubled to ₹253.01 Cr, up 99.2% YoY from ₹127.04 Cr and 42.4% QoQ from ₹177.64 Cr. Consolidated PAT surged 163.0% YoY to ₹20.40 Cr (from ₹7.76 Cr) and 166.5% QoQ (from ₹7.65 Cr), with EPS at ₹8.18 versus ₹3.11 a year ago and ₹3.07 last quarter. Standalone figures (revenue ₹252.99 Cr, PAT ₹20.41 Cr) are effectively identical to consolidated — the sole subsidiary, DMCC (Europe) GmbH, added just ₹1.64 lakh of revenue this quarter, so the two bases tell the same story.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹253.01 Cr+42.4%+99.2%
Expenses₹226.1 Cr+35.4%+94.3%
PAT₹20.4 Cr+166.51%+163.04%
Net margin8.05%+3.8pp+2pp
EPS₹8.18+166.4%+163%

Net profit margin expanded to 8.05% of total income, from 6.09% a year ago and 4.30% last quarter. EBITDA-level operating margin came in at 13.59%, up sharply from 9.96% QoQ but only marginally above the 13.28% posted a year ago. The margin gain is a volume story, not cost relief: raw-material consumption rose to roughly 78% of total income this quarter versus about 61% a year ago, consistent with the raw-material price pressure management flagged on the FY26 Q4 call. Total expenses grew 94.2% YoY to ₹226.08 Cr, just below revenue's 99.2% growth — enough operating leverage to lift margins modestly, but the cost structure is visibly heavier than a year ago. No exceptional items appear in either period, so the growth is entirely operating.

227.28253.69280.1306.51332.9231605-0705-2906-2207-1508-0608-10Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹316, up 19.2% over the past month of trading.

₹ Cr
07.6215.2322.856.47Q4 FY25rev ₹125 Cr7.76Q1 FY26rev ₹127 Cr5.75Q2 FY26rev ₹126 Cr6.17Q3 FY26rev ₹151 Cr7.65Q4 FY26rev ₹178 Cr20.4Q1 FY27rev ₹253 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

What management guided (4 FY-2026 call)
Management indicated that while the current situation remains volatile, they expect FY27 to be better than FY25-26 for the specialty chemical segment, though precise projections are difficult. They are seeing some initial commercial sales in new specialty products, particularly in boron derivatives, and expect to incre

This quarter: beat

On the FY26 Q4 call, management guided that FY27 would be better than FY25-26 for the specialty chemicals segment while flagging near-term volatility, raw-material and working-capital pressure, and early boron-derivative commercial traction; a subsequent earnings-call summary also noted a bearish boron market tied to an energy-driven supply glut expected to weigh on demand into Q1 FY27. Against that cautious framing, a near-doubling of revenue and 163% YoY profit growth reads as a clear beat of the qualitative guidance, even as the flagged raw-material cost pressure shows up in the expense mix. No brokerage consensus or published Q1 FY27 preview for DMCC could be found, so there is no street number to benchmark against, and no separate management press release accompanied this filing. The only other disclosed development this quarter is a minor ₹1.06 Cr ITC demand appeal from May, immaterial to the P&L. Results are unaudited, with the statutory auditor issuing an unmodified limited-review opinion on both statements.

  • W1

    Whether raw-material cost intensity (~78% of revenue in Q1 FY27 vs ~61% YoY) eases in Q2 FY27, as management said it expects to manage the pressure

  • W2

    Boron-derivative specialty-product ramp and rising R&D intensity flagged in the FY26 Q4 call — watch for commercial traction/mix disclosure

  • W3

    Progress toward management's stated goal of specialty chemicals reaching at least 50% of total revenue

Informational and educational content only. Not investment advice.

DMCC Speciality Chemicals Ltd (DMCC) Q1 FY27 Results — StockWatch